Unicycive Therapeutics, Inc. (UNCY) financial statements and ratios from SEC XBRL: revenue $1.01M (TTM), net margin -2624.0%, revenue growth -19.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.01M |
| Net Margin | -2624.0% |
| Revenue Growth (YoY) | -19.7% |
| EPS Growth (YoY) | 198.2% |
| FCF Growth (YoY) | 9.4% |
| Price / Book | 2.82 |
| Price / Sales | 99.68 |
| FCF Yield | -33.0% |
| Altman Z-Score | -0.37 (distress) |
| Sector P/E (Healthcare) | 21.7 |
UNCY overview · UNCY earnings · UNCY KPIs · UNCY investor relations · UNCY ownership · UNCY peers · UNCY filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.